The study met all primary and secondary endpoints, showing greater improvements compared to standard therapy
Retatrutide (LY3437943) is a synthetic 39-amino acid unimolecular triple-hormone receptor agonist and is supplied exclusively for laboratory and preclinical research applications
For a given rise in plasma glucose concentration, the increase in plasma insulin is roughly threefold times greater, if glucose is administered orally compared to intravenous route (Perley and Kipnis, 1967)
Lifestyle changes, primary care monitoring, FDA-approved medications, diabetes treatment, nutrition support, and chronic disease management can help now
[PMID: 9066504] PubMed record related to this compound for laboratory literature review